MDT

Medtronic Plc: Q1 2026 (Ended July 25, 2025) Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the three-month period ended July 25, 2025 (Q1 Fiscal 2026). Medtronic Plc is a global healthcare technology company operating through four reportable segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. In May 2025, the Company announced its intent to separate the Diabetes business into an independent, publicly traded company, with completion expected within 18 months.

Key Financial Metrics

Note: Operating margin was approximately 16.8% for the current period. The effective tax rate was 19.6%.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 8% year-over-year, driven by organic growth in Cardiac Ablation, TAVR, Neuromodulation, and Diabetes, as well as a $39 million favorable adjustment to Italian payback accruals (compared to a $90 million unfavorable adjustment in the prior year).
• Segment Performance:
  • Cardiovascular: Sales up 9% ($3.3B), led by Micra pacemakers and Evolut FX+ TAVR.
  • Neuroscience: Sales up 4% ($2.4B), driven by Neuromodulation and Core Spine.
  • Medical Surgical: Sales up 4% ($2.1B), with growth in Advanced Energy and Acute Care.
  • Diabetes: Sales up 12% ($721M), driven by MiniMed 780G adoption.
• Expenses: Cost of products sold rose to $3.0B. R&D increased to $726M. SG&A increased to $2.8B due to new product launches. Amortization of intangible assets increased to $459M, including $45M of accelerated amortization in Cardiovascular.
• Investment Losses: The Company recognized a $90 million unrealized loss on its Mozarc Medical investment (50% stake in kidney care joint venture), impacting non-operating income.

Outlook, Risks, and Management Commentary

• Guidance & Outlook: Management expects continued growth in key product lines (Micra, Evolut FX+, Inceptiv SCS, MiniMed 780G). The Diabetes separation is proceeding as planned.
• Tariff Impact: Based on rates as of August 19, 2025, the Company estimates a pre-tax net tariff impact of $185 million in Fiscal 2026, with the majority recognized in the second half of the year.
• Geopolitical Risks: The Russia-Ukraine conflict and Israel conflict had an immaterial financial impact in Q1 (less than 1% of consolidated revenues/assets). However, ongoing trade policy uncertainties remain a risk.
• Legal & Contingencies:
  • Colibri Litigation: The U.S. Court of Appeals ruled in Medtronic's favor, vacating a $106M jury verdict regarding patent infringement.
  • Hernia Mesh: Approximately 9,350 lawsuits pending; no loss accrued as it is not currently probable or estimable.
  • Applied Medical Antitrust: Motion for summary judgment denied; trial date not set.
  • Italian Payback: Liability reduced by $39M in Q1 due to new legislation, though litigation for years 2019+ remains pending.
• Capital Allocation: The Company repurchased 1.4 million shares for $123 million. Approximately $2.0 billion remains under the $5.0 billion share repurchase authorization. Dividends paid were $0.71 per share.

Investor Verification Checklist

• Italian Payback Liability: Verify the stability of the $39M revenue adjustment and the remaining exposure for years 2019 and beyond.
• Tariff Exposure: Confirm the $185M estimated tariff impact for Fiscal 2026 and potential mitigation strategies.
• Diabetes Separation: Monitor progress on the 18-month timeline for the spin-off and associated transaction costs.
• Mozarc Medical Valuation: Assess the drivers of the $90M unrealized loss on the kidney care joint venture and future fair value volatility.
• Legal Reserves: Review the status of the Applied Medical antitrust case and Hernia Mesh litigation for potential future accruals.
• Accelerated Amortization: Understand the specific intangible assets in the Cardiovascular segment subject to the $45M accelerated write-down.